Successful life sciences deal-making requires the ability to navigate the here and now while also trying to see around corners and predict the future. For those at BIO, join me tomorrow (June 5) for a deep dive into the current choppy waters of deal-making in the current markets, where I have the privilege of talking with Barbara Kosacz, Joseph Baroldi and Stacy Feld to share their insights and perspectives from decades of collective experience across various sectors of the life sciences and biotech industry, including roles as C-suite executives, investors, legal counsel, and board members in a range of life sciences companies and investment funds. https://lnkd.in/gz_ZKaBX
Kate Hillier’s Post
More Relevant Posts
-
🧬 European Life Sciences deals overview for 2023 & 2024 outlook 📈 https://lnkd.in/dsiQ5NpB Excited to share our latest publication. In this report, we delve into the dynamic landscape of life sciences investments across European targets, highlighting key trends across each deal type, notable deals, and emerging opportunities shaping the industry Explore the full report to stay informed and gain strategic perspectives on the future of life sciences investments in Europe #LifeSciences #Biotech #Investments
Overview and outlook of European Life Sciences deals 2023 & 2024
kpmg.com
-
Biotech Equity Research: Tracking The Promise (And Risk) Of Early Stage Companies Navigating The Public Markets October 3, 2024, 3:00 – 4:00 p.m. EST Speaker: Benjamin J. Burnett, PhD, Managing Director, Equity Research, Stifel Investment Services Ben Burnett, Biotech Equity Research Analyst at Stifel will discuss the intersection of early stage life science companies and finance. We plan to cover recent capital market trends and forecasts, timing the market, and what it takes to become (and be) a public company. Balancing innovation with capital needs requires a good understanding of how and when to access capital, and whether or not this is more easily done as a private or public company. We plan to delve into these concepts in detail and walk through informative case studies of both success and failure. Zoom Registration: https://lnkd.in/e-hHmpN7
Welcome! You are invited to join a meeting: CNYBAC presents Biotech Equity Research: Tracking the Promise (and Risk) of Early Stage Companies Navigating the Public Markets, Benjamin Burnett, PhD. After registering, you will receive a confirmation email about joining the meeting.
upstate.zoom.us
-
If US regulatory, compliance, and business risks in life sciences transactions is in your bailiwick, then this webinar with the profound Hemmie Chang will be highly relevant.
Join us for a webinar tailored for in-house counsel, business development leads, and private equity and venture capital investors in the life sciences sector. Arnold & Porter partner Hemmie Chang and senior associate Phillip V. DeFedele will discuss mitigating major FDA regulatory, compliance, and business risks in life sciences transactions, including: • Minimizing risks for pre-commercial assets • Post-signing/pre-closing risk mitigation • Regulatory and compliance considerations for integration • Managing ongoing investigations and enforcement Gain insights on navigating complex regulatory and business challenges in life sciences M&A and licensing deals. Register today ➡️ https://bit.ly/4bU2qIJ #LifeSciences
-
-
Taking on the role of a biotech CEO can be a daunting prospect, especially when it is your first time in the position. The journey in this industry is marked by a unique set of hurdles including scientific complexities, regulatory intricacies, and interactions with a wide range of stakeholders. In this dynamic landscape, the role of the Chair of the Board of Directors becomes pivotal, as they are well-positioned to empower and support first-time CEOs. V-Bio Ventures Senior Executive Shelley Margetson shares her insights on the benefits of a supportive relationship between a new biotech CEO and their Board Chair. https://lnkd.in/eACx4F3p #executive #biotech #VentureCapital
-
-
Oceanrock Insights Launches: Private Equity Opportunities in the GLP-1 Market 💡At Oceanrock, we are dedicated to enhancing our world-class service. Recognising that there is room for improvement in delivering high-level insights and drawing out key messages from our work, we have introduced 'Oceanrock Insights'. This initiative allows our analysts to work closely with our Insights Champion, Nic Bryant, and positively challenge each other as they refine their chosen topics and distill key messages into concise, punchy one-pagers. 🤝Credit to our first group of analysts—Simon Haddon, Tamarin Smal, Anaas Jeebun, FMVA®, Stefan Janse van Vuuren, CFA, and Maximilian van der Lecq. 💎The featured piece focuses on the burgeoning GLP-1 market, projected to reach $167 billion by 2031. Despite the dominance of industry heavyweights like Novo Nordisk and Eli Lilly, our analysis identifies opportunities for private equity firms to carve out their niche and capture substantial value. 💬Feel free to download the content from the link to our website (https://lnkd.in/dsEtUdHd), and join the conversation on our posts that catch your interest.
-
-
MARKET TREND: MONEY MOVES The biotech market has continued to see investment growth so far in 2024. High-profile initial public offerings from industry players like CG Oncology, Arrivent Biopharms and Kyverna experienced double-digit stock price growth after entering the market. 📈 This may be an indicator of what is coming next for biotech: more IPOs, and eventually, a more competitive commercial real estate sector in this industry. 🏢 What do you think of this prediction? At 95 Greene, we’re lab-ready and built for companies to make their next discovery. 🔬🧬 Thor Equities Group | SGA (Boston | New York) | McNamara • Salvia, Structural Engineers | Vanderweil Engineers | Sweet Group LLC | JLL | Blake Goodman | Daniel Spero | John Cahill | Craig Eisenhardt | Robert Ryan | Dan Loughlin #95GreeneSt #NJRealEstate #LifeSciences #IPO #CBRE
-
🧠 💰 Smart Financial Moves for Life Sciences Pioneers 🙏 A big thank you to Jody Staggs from SWK Holdings Corporation for the insights in: "Five Financial Strategies Life Sciences Companies Should Consider" 🔍 The article captures the importance of balancing innovation with financial prudence by: 1️⃣ diversifying funding sources 2️⃣ exploring alternative finance structures like royalty financing, and; 3️⃣ prioritising key clinical milestones 💡 A standout point for us, in relation to vendor management and oversight for clinical development, is the emphasis on prioritising key clinical milestones. This approach is crucial for guiding strategic partnerships and maintaining focused, goal-oriented collaborations. It underscores the importance of strategic decision-making in funding and operational management to drive clinical objectives. 🔗 See full article here: https://lnkd.in/eEPBpT5t #lifesciences #clinicaldevelopment #financestrategy #risk #pharma #biotech #clinicaltrials
-
-
Are you an investor and interested in supporting our local life sciences ecosystem? Our upcoming #LifeSciencesSummit is only possible with the participation of angel investors to help our local life sciences companies raise capital and fast-track their success! We know what you're thinking - investing is complicated and requires a lot of professional level due diligence, and the life sciences regulatory environment adds even more complexity. That's why we have prepared a unique session to tell you everything you need to know about investing in the life sciences and set you up for closing a successful deal! Join API and Startup TNT at our Angel 101 online sessions with HaloHealth, this January 16 and 18. Whether you're new or experienced in investing, these sessions will help you to: 🔍 Gain valuable insights into the current state of investing in life sciences. 📈 Discover the latest trends shaping the life sciences industry. 💡 Learn how to identify lucrative investment opportunities. 🤝 Build connections within a vibrant community of investors and professionals. 🌐 Expand your network and uncover potential partnerships. Don't miss out on this incredible opportunity! Secure your spot now 👉 https://lnkd.in/gjxTYzAV
-
-
Epoch 10: Beyond the Bucks - How Specialist Investors Fuel Biotech Success Does the quality of investors on the cap table influence the long term success of the company? 👉 Investor quality drives market cap? 👉 Investor quality can revive neg EV biotechs? 👉 M&A likelihood correlated to investor quality? 👉 M&A returns correlated to investor quality? https://lnkd.in/dEkBy2bY
-